Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate ...

TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...